AB-2100 Cell Therapy for Kidney Cancer
Trial Summary
What is the purpose of this trial?
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
Will I have to stop taking my current medications?
The trial requires that you stop any prior systemic kidney cancer therapy at least 14 days before cell collection, and any systemic anti-cancer therapy at least 14 days before starting conditioning chemotherapy. If your last treatment included an antibody-based agent, you need to wait 28 days.
What data supports the effectiveness of the treatment AB-2100 for kidney cancer?
Research shows that immunotherapy, which includes treatments that activate the body's immune system to fight cancer, has been promising for kidney cancer. Studies have explored various immune-based treatments, such as those using specific immune cells, which have shown encouraging results in targeting kidney cancer.12345
How is the AB-2100 treatment for kidney cancer different from other treatments?
AB-2100 is a cell therapy, which is a type of treatment that uses living cells to fight cancer, and it is part of a new wave of treatments focusing on the immune system's ability to target cancer cells. This approach is different from traditional treatments like chemotherapy and radiotherapy, which often have limited effectiveness in kidney cancer.12367
Research Team
Arsenal Biosciences
Principal Investigator
Arsenal Biosciences
Eligibility Criteria
This trial is for people who have had kidney cancer (clear-cell Renal Cell Carcinoma) come back after treatment. Specific details about who can join are not provided, but typically participants need to meet certain health standards and may be excluded based on factors that could affect the study or their safety.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Conditioning Chemotherapy
Participants receive fludarabine and cyclophosphamide intravenously over 3 consecutive days to prepare the body for AB-2100 cell infusion
Treatment
Participants receive a single dose of AB-2100 cells intravenously
Follow-up
Participants are monitored for safety, tolerability, and response after treatment
Treatment Details
Interventions
- AB-2100
Find a Clinic Near You
Who Is Running the Clinical Trial?
Arsenal Biosciences, Inc.
Lead Sponsor